Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients. (2024). Biomolecules and Biomedicine, 24(6), 1586–1594. https://doi.org/10.17305/bb.2024.10528